Podcasts about Lung cancer screening

In this second episode of our lung cancer miniseries, Jonathan Sackier is joined by David Baldwin, a leading expert in screening, epidemiology, and policy. Baldwin reflects on national screening programmes, groundbreaking trials, and how AI, big data, and evidence-based guidelines are reshaping lung cancer care. Timestamps: 00:00 – Introduction 03:17 – Key takeaways from the UKLS trial 11:10 – Boosting participation in screening studies 17:04 – The Targeted Lung Health Check programme 23:30 – Understanding large datasets in lung cancer epidemiology 32:44 – AI and big data in lung cancer imaging 41:43 – Shaping national guidelines 47:47 – Are we doing enough to prevent lung cancer? 53:06 – Baldwin's three wishes for healthcare

Dr. Nathan Pennell and Dr. Cheryl Czerlanis discuss challenges in lung cancer screening and potential solutions to increase screening rates, including the use of AI to enhance risk prediction and screening processes. Transcript Dr. Nate Pennell: Hello, and welcome to By the Book, a monthly podcast series for ASCO Education that features engaging discussions between editors and authors from the ASCO Educational Book. I'm Dr. Nate Pennell, the co-director of the Cleveland Clinic Lung Cancer Program and vice chair of clinical research for the Taussig Cancer Center. I'm also the editor-in-chief for the ASCO Educational Book.  Lung cancer is one of the leading causes of cancer-related mortality worldwide, and most cases are diagnosed at advanced stages where curative treatment options are limited. On the opposite end, early-stage lung cancers are very curable. If only we could find more patients at that early stage, an approach that has revolutionized survival for other cancer types such as colorectal and breast cancer.  On today's episode, I'm delighted to be joined by Dr. Cheryl Czerlanis, a professor of medicine and thoracic medical oncologist at the University of Wisconsin Carbone Cancer Center, to discuss her article titled, "Broadening the Net: Overcoming Challenges and Embracing Novel Technologies in Lung Cancer Screening." The article was recently published in the ASCO Educational Book and featured in an Education Session at the 2025 ASCO Annual Meeting. Our full disclosures are available in the transcript of this episode.  Cheryl, it's great to have you on the podcast today. Thanks for being here. Dr. Cheryl Czerlanis: Thanks, Nate. It's great to be here with you. Dr. Nate Pennell: So, I'd like to just start by asking you a little bit about the importance of lung cancer screening and what evidence is there that lung cancer screening is beneficial. Dr. Cheryl Czerlanis: Thank you. Lung cancer screening is extremely important because we know that lung cancer survival is closely tied to stage at diagnosis. We have made significant progress in the treatment of lung cancer, especially over the past decade, with the introduction of immunotherapies and targeted therapies based on personalized evaluation of genomic alterations. But the reality is that outside of a lung screening program, most patients with lung cancer present with symptoms related to advanced cancer, where our ability to cure the disease is more limited.  While lung cancer screening has been studied for years, the National Lung Screening Trial, or the NLST, first reported in 2011 a significant reduction in lung cancer deaths through screening. Annual low-dose CT scans were performed in a high-risk population for lung cancer in comparison to chest X-ray. The study population was comprised of asymptomatic persons aged 55 to 74 with a 30-pack-year history of smoking who were either active smokers or had quit within 15 years. The low-dose CT screening was associated with a 20% relative risk reduction in lung cancer-related mortality. A similar magnitude of benefit was also reported in the NELSON trial, which was a large European randomized trial comparing low-dose CT with a control group receiving no screening. Dr. Nate Pennell: So, this led, of course, to approval from CMS (Centers for Medicare and Medicaid Services) for lung cancer screening in the Medicare population, probably about 10 years ago now, I think. And there are now two major trials showing an unequivocal reduction in lung cancer-related mortality and even evidence that it reduces overall mortality with lung cancer screening. But despite this, lung cancer screening rates are very low in the United States. So, first of all, what's going on? Why are we not seeing the kinds of screening rates that we see with mammography and colonoscopy? And what are the barriers to that here? Dr. Cheryl Czerlanis: That's a great question. Thank you, Nate. In the United States, recruitment for lung cancer screening programs has faced numerous challenges, including those related to socioeconomic, cultural, logistical, and even racial disparities. Our current lung cancer screening guidelines are somewhat imprecise and often fail to address differences that we know exist in sex, smoking history, socioeconomic status, and ethnicity. We also see underrepresentation in certain groups, including African Americans and other minorities, and special populations, including individuals with HIV. And even where lung cancer screening is readily available and we have evidence of its efficacy, uptake can be low due to both provider and patient factors. On the provider side, barriers include having insufficient time in a clinic visit for shared decision-making, fear of missed test results, lack of awareness about current guidelines, concerns about cost, potential harms, and evaluating both true and false-positive test results.  And then on the patient side, barriers include concerns about cost, fear of getting a cancer diagnosis, stigma associated with tobacco smoking, and misconceptions about the treatability of lung cancer. Dr. Nate Pennell: I think those last two are really what make lung cancer unique compared to, say, for example, breast cancer, where there really is a public acceptance of the value of mammography and that breast cancer is no one's fault and that it really is embraced as an active way you can take care of yourself by getting your breast cancer screening. Whereas in lung cancer, between the stigma of smoking and the concern that, you know, it's a death sentence, I think we really have some work to be made up, which we'll talk about in a minute about what we can do to help improve this.  Now, that's in the U.S. I think things are probably, I would imagine, even worse when we leave the U.S. and look outside, especially at low- and middle-income countries. Dr. Cheryl Czerlanis: Yes, globally, this issue is even more complex than it is in the United States. Widespread implementation of low-dose CT imaging for lung cancer screening is limited by manpower, infrastructure, and economic constraints. Many low- and middle-income countries even lack sufficient CT machines, trained personnel, and specialized facilities for accurate and timely screenings. Even in urban centers with advanced diagnostic facilities, the high screening and follow-up care costs can limit access. Rural populations face additional barriers, such as geographic inaccessibility of urban centers, transportation costs, language barriers, and mistrust of healthcare systems. In addition, healthcare systems in these regions often prioritize infectious diseases and maternal health, leaving limited room for investments in noncommunicable disease prevention like lung cancer screening. Policymakers often struggle to justify allocating resources to lung cancer screening when immediate healthcare needs remain unmet. Urban-rural disparities exacerbate these challenges, with rural regions frequently lacking the infrastructure and resources to sustain screening programs. Dr. Nate Pennell: Well, it's certainly an intimidating problem to try to reduce these disparities, especially between the U.S. and low- and middle-income countries. So, what are some of the potential solutions, both here in the U.S. and internationally, that we can do to try to increase the rates of lung cancer screening? Dr. Cheryl Czerlanis: The good news is that we can take steps to address these challenges, but a multifaceted approach is needed. Public awareness campaigns focused on the benefits of early detection and dispelling myths about lung cancer screening are essential to improving participation rates. Using risk-prediction models to identify high-risk individuals can increase the efficiency of lung cancer screening programs. Automated follow-up reminders and screening navigators can also ensure timely referrals and reduce delays in diagnosis and treatment. Reducing or subsidizing the cost of low-dose CT scans, especially in low- or middle-income countries, can improve accessibility. Deploying mobile CT scanners can expand access to rural and underserved areas.  On a global scale, integrating lung cancer screening with existing healthcare programs, such as TB or noncommunicable disease initiatives, can enhance resource utilization and program scalability. Implementing lung cancer screening in resource-limited settings requires strategic investment, capacity building, and policy interventions that prioritize equity. Addressing financial constraints, infrastructure gaps, and sociocultural barriers can help overcome existing challenges. By focusing on cost-effective strategies, public awareness, and risk-based eligibility criteria, global efforts can promote equitable access to lung cancer screening and improve outcomes.  Lastly, as part of the medical community, we play an important role in a patient's decision to pursue lung cancer screening. Being up to date with current lung cancer screening recommendations, identifying eligible patients, and encouraging a patient to undergo screening often is the difference-maker. Electronic medical record (EMR) systems and reminders are helpful in this regard, but relationship building and a recommendation from a trusted provider are really essential here. Dr. Nate Pennell: I think that makes a lot of sense. I mean, there are technology improvements. For example, our lung cancer screening program at The Cleveland Clinic, a few years back, we finally started an automated best practice alert in our EMR for patients who met the age and smoking requirements, and it led to a six-fold increase in people referred for screening. But at the same time, there's a difference between just getting this alert and putting in an order for lung cancer screening and actually getting those patients to go and actually do the screening and then follow up on it. And that, of course, requires having that relationship and discussion with the patient so that they trust that you have their best interests. Dr. Cheryl Czerlanis: Exactly. I think that's important. You know, certainly, while technology can aid in bringing patients in, there really is no substitute for trust-building and a personal relationship with a provider. Dr. Nate Pennell: I know that there are probably multiple examples within the U.S. where health systems or programs have put together, I would say, quality improvement projects to try to increase lung cancer screening and working with their community. There's one in particular that you discuss in your paper called the "End Lung Cancer Now" initiative. I wonder if you could take us through that. Dr. Cheryl Czerlanis: Absolutely. "End Lung Cancer Now" is an initiative at the Indiana University Simon Comprehensive Cancer Center that has the vision to end suffering and death from lung cancer in Indiana through education and community empowerment. We discuss this as a paradigm for how community engagement is important in building and scaling a lung cancer screening program.  In 2023, the "End Lung Cancer Now" team decided to focus its efforts on scaling and transforming lung cancer screening rates in Indiana. They developed a task force with 26 experts in various fields, including radiology, pulmonary medicine, thoracic surgery, public health, and advocacy groups. The result of this work is an 85-page blueprint with key recommendations that any system and community can use to scale lung cancer screening efforts. After building strong infrastructure for lung cancer screening at Indiana University, they sought to understand what the priorities, resources, and challenges in their communities were. To do this, they forged strong partnerships with both local and national organizations, including the American Lung Association, American Cancer Society, and others. In the first year, they actually tripled the number of screening low-dose CTs performed in their academic center and saw a 40% increase system-wide. One thing that I think is the most striking is that through their community outreach, they learned that most people prefer to get medical care close to home within their own communities. Establishing a way to support the local infrastructure to provide care became far more important than recruiting patients to their larger system.  In exciting news, "End Lung Cancer Now" has partnered with the IU Simon Comprehensive Cancer Center and IU Health to launch Indiana's first and only mobile lung screening program in March of 2025. This mobile program travels around the state to counties where the highest incidence of lung cancer exists and there is limited access to screening. The mobile unit parks at trusted sites within communities and works in partnership, not competition, with local health clinics and facilities to screen high-risk populations. Dr. Nate Pennell: I think that sounds like a great idea. Screening is such an important thing that it doesn't necessarily have to be owned by any one particular health system for their patients. I think. And I love the idea of bringing the screening to patients where they are. I can speak to working in a regional healthcare system with a main campus in the downtown that patients absolutely hate having to come here from even 30 or 40 minutes away, and they'd much rather get their care locally. So that makes perfect sense.  So, under the current guidelines, there are certainly things that we can do to try to improve capturing the people that meet those. But are those guidelines actually capturing enough patients with lung cancer to make a difference? There certainly are proposals within patient advocacy communities and even other countries where there's a large percentage of non-smokers who perhaps get lung cancer. Can we expand beyond just older, current and heavy smokers to identify at-risk populations who could benefit from screening? Dr. Cheryl Czerlanis: Yes, I think we can, and it's certainly an active area of research interest. We know that tobacco is the leading cause of lung cancer worldwide. However, other risk factors include secondhand smoke, family history, exposure to environmental carcinogens, and pulmonary diseases like COPD and interstitial lung disease. Despite these known associations, the benefit of lung cancer screening is less well elucidated in never-smokers and those at risk of developing lung cancer because of family history or other risk factors. We know that the eligibility criteria associated with our current screening guidelines focus on age and smoking history and may miss more than 50% of lung cancers. Globally, 10% to 25% of lung cancer cases occur in never-smokers. And in certain parts of the world, like you mentioned, Nate, such as East Asia, many lung cancers are diagnosed in never-smokers, especially in women. Risk-prediction models use specific risk factors for lung cancer to enhance individual selection for screening, although they have historically focused on current or former smokers.  We know that individuals with family members affected by lung cancer have an increased risk of developing the disease. To this end, several large-scale, single-arm prospective studies in Asia have evaluated broadening screening criteria to never-smokers, with or without additional risk factors. One such study, the Taiwan Lung Cancer Screening in Never-Smoker Trial, was a multicenter prospective cohort study at 17 medical centers in Taiwan. The primary outcome of the TALENT trial was lung cancer detection rate. Eligible patients aged 55 to 75 had either never smoked or had a light and remote smoking history. In addition, inclusion required one or more of the following risk factors: family history of lung cancer, passive smoke exposure, history of TB or COPD, a high cooking index, which is a metric that quantifies exposure to cooking fumes, or a history of cooking without ventilation. Participants underwent low-dose CT screening at baseline, then annually for 2 years, and then every 2 years for up to 6 years. The lung cancer detection rate was 2.6%, which was higher than that reported in the NLST and NELSON trials, and most were stage 0 or I cancers. Subsequently, this led to the Taiwan Early Detection Program for Lung Cancer, a national screening program that was launched in 2022, targeting 2 screening populations: individuals with a heavy history of smoking and individuals with a family history of lung cancer.  We really need randomized controlled trials to determine the true rates of overdiagnosis or finding cancers that would not lead to morbidity or mortality in persons who are diagnosed, and to establish whether the high lung detection rates are associated with a decrease in lung cancer-related mortality in these populations. However, the implementation of randomized controlled low-dose CT screening trials in never-smokers has been limited by the need for large sample sizes, lengthy follow-up, and cost.  In another group potentially at higher risk for developing lung cancer, the role of lung cancer screening in individuals who harbor germline pathogenic variants associated with lung cancer also needs to be explored further. Dr. Nate Pennell: We had this discussion when the first criteria came out because there have always been risk-based calculators for lung cancer that certainly incorporate smoking but other factors as well and have discussion about whether we should be screening people based on their risk and not just based on discrete criteria such as smoking. But of course, the insurance coverage for screening, you have to fit the actual criteria, which is very constrained by age and smoking history. Do you think in the U.S. there's hope for broadening our screening beyond NLST and NELSON criteria? Dr. Cheryl Czerlanis: I do think at some point there is hope for broadening the criteria beyond smoking history and age, beyond the criteria that we have typically used and that is covered by insurance. I do think it will take some work to perhaps make the prediction models more precise or to really understand who can benefit. We certainly know that there are many patients who develop lung cancer without a history of smoking or without family history, and it would be great if we could diagnose more patients with lung cancer at an earlier stage. I think this will really count on there being some work towards trying to figure out what would be the best population for screening, what risk factors to look for, perhaps using some new technologies that may help us to predict who is at risk for developing lung cancer, and trying to increase the group that we study to try and find these early-stage lung cancers that can be cured. Dr. Nate Pennell: Part of the reason we, of course, try to enrich our population is screening works better when you have a higher pretest probability of actually having cancer. And part of that also is that our technology is not that great. You know, even in high-risk patients who have CT scans that are positive for a screen, we know that the vast majority of those patients with lung nodules actually don't have lung cancer. And so you have to follow them, you have to use various models to see, you know, what the risk, even in the setting of a positive screen, is of having lung cancer.  So, why don't we talk about some newer tools that we might use to help improve lung cancer screening? And one of the things that everyone is super excited about, of course, is artificial intelligence. Are there AI technologies that are helping out in early detection in lung cancer screening? Dr. Cheryl Czerlanis: Yes, that's a great question. We know that predicting who's at risk for lung cancer is challenging for the reasons that we talked about, knowing that there are many risk factors beyond smoking and age that are hard to quantify. Artificial intelligence is a tool that can help refine screening criteria and really expand screening access. Machine learning is a form of AI technology that is adept at recognizing patterns in large datasets and then applying the learning to new datasets. Several machine learning models have been developed for risk stratification and early detection of lung cancer on imaging, both with and without blood-based biomarkers. This type of technology is very promising and can serve as a tool that helps to select individuals for screening by predicting who is likely to develop lung cancer in the future.  A group at Massachusetts General Hospital, represented in our group for this paper by my co-authors, Drs. Fintelmann and Chang, developed Sybil, which is an open-access 3D convolutional neural network that predicts an individual's future risk of lung cancer based on the analysis of a single low-dose CT without the need for human annotation or other clinical inputs. Sybil and other machine learning models have tremendous potential for precision lung cancer screening, even, and perhaps especially, in settings where expert image interpretation is unavailable. They could support risk-adapted screening schedules, such as varying the frequency and interval of low-dose CT scans according to individual risk and potentially expand lung cancer screening eligibility beyond age and smoking history. Their group predicts that AI tools like Sybil will play a major role in decoding the complex landscape of lung cancer risk factors, enabling us to extend life-saving lung cancer screening to all who are at risk. Dr. Nate Pennell: I think that that would certainly be welcome. And as AI is working its way into pretty much every aspect of life, including medical care, I think it's certainly promising that it can improve on our existing technology.  We don't have to spend a lot of time on this because I know it's a little out of scope for what you covered in your paper, but I'm sure our listeners are curious about your thoughts on the use of other types of testing beyond CT screening for detecting lung cancer. I know that there are a number of investigational and even commercially available blood tests, for example, for detection of lung cancer, or even the so-called multi-cancer detection blood tests that are now being offered, although not necessarily being covered by insurance, for multiple types of cancer, but lung cancer being a common cancer is included in that. So, what do you think? Dr. Cheryl Czerlanis: Yes, like you mentioned, there are novel bioassays such as blood-based biomarker testing that evaluate for DNA, RNA, and circulating tumor cells that are both promising and under active investigation for lung cancer and multi-cancer detection. We know that such biomarker assays may be useful in both identifying lung cancers but also in identifying patients with a high-risk result who should undergo lung cancer screening by conventional methods. Dr. Nate Pennell: Anything that will improve on our rate of screening, I think, will be welcome. I think probably in the future, it will be some combination of better risk prediction and better interpretation of screening results, whether those be imaging or some combination of imaging and biomarkers, breath-based, blood-based. There's so much going on that it is pretty exciting, but we're still going to have to overcome the stigma and lack of public support for lung cancer screening if we're going to move the needle. Dr. Cheryl Czerlanis: Yes, I think moving the needle is so important because we know lung cancer is still a very morbid disease, and our ability to cure patients is not where we would like it to be. But I do believe there's hope. There are a lot of motivated individuals and groups who are passionate about lung cancer screening, like myself and my co-authors, and we're just happy to be able to share some ways that we can overcome the challenges and really try and make an impact in the lives of our patients. Dr. Nate Pennell: Well, thank you, Dr. Czerlanis, for joining me on the By the Book Podcast today and for all of your work to advance care for patients with lung cancer. Dr. Cheryl Czerlanis: Thank you, Dr. Pennell. It's such a pleasure to be with you today. Thank you. Dr. Nate Pennell: And thank you to our listeners for joining us today. You'll find a link to Dr. Czerlanis' article in the transcript of this episode.  Please join us again next month for By the Book's next episode and more insightful views on topics you'll be hearing at the education sessions from ASCO meetings throughout the year, and our deep dives on approaches that are shaping modern oncology. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Follow today's speakers:     Dr. Nathan Pennell    @n8pennell   @n8pennell.bsky.social Dr. Cheryl Czerlanis Follow ASCO on social media:     @ASCO on X (formerly Twitter)     ASCO on Bluesky    ASCO on Facebook     ASCO on LinkedIn     Disclosures:    Dr. Nate Pennell:        Consulting or Advisory Role: AstraZeneca, Lilly, Cota Healthcare, Merck, Bristol-Myers Squibb, Genentech, Amgen, G1 Therapeutics, Pfizer, Boehringer Ingelheim, Viosera, Xencor, Mirati Therapeutics, Janssen Oncology, Sanofi/Regeneron       Research Funding (Institution): Genentech, AstraZeneca, Merck, Loxo, Altor BioScience, Spectrum Pharmaceuticals, Bristol-Myers Squibb, Jounce Therapeutics, Mirati Therapeutics, Heat Biologics, WindMIL, Sanofi    Dr. Cheryl Czerlanis: Research Funding (Institution): LungLife AI, AstraZeneca, Summit Therapeutics

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/KDS865. CME/MOC/AAPA credit will be available until June 6, 2026.Facilitating Progress in Early Detection & Intervention in Lung Cancer: Proactive Strategies to Improve Lung Cancer Screening for High-Risk Individuals in VA Healthcare Settings In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and National Association of Veterans' Research and Education Foundations. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an independent educational grant from Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/KDS865. CME/MOC/AAPA credit will be available until June 6, 2026.Facilitating Progress in Early Detection & Intervention in Lung Cancer: Proactive Strategies to Improve Lung Cancer Screening for High-Risk Individuals in VA Healthcare Settings In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and National Association of Veterans' Research and Education Foundations. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an independent educational grant from Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/KDS865. CME/MOC/AAPA credit will be available until June 6, 2026.Facilitating Progress in Early Detection & Intervention in Lung Cancer: Proactive Strategies to Improve Lung Cancer Screening for High-Risk Individuals in VA Healthcare Settings In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and National Association of Veterans' Research and Education Foundations. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an independent educational grant from Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/KDS865. CME/MOC/AAPA credit will be available until June 6, 2026.Facilitating Progress in Early Detection & Intervention in Lung Cancer: Proactive Strategies to Improve Lung Cancer Screening for High-Risk Individuals in VA Healthcare Settings In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and National Association of Veterans' Research and Education Foundations. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an independent educational grant from Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/KDS865. CME/MOC/AAPA credit will be available until June 6, 2026.Facilitating Progress in Early Detection & Intervention in Lung Cancer: Proactive Strategies to Improve Lung Cancer Screening for High-Risk Individuals in VA Healthcare Settings In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and National Association of Veterans' Research and Education Foundations. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an independent educational grant from Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/KDS865. CME/MOC/AAPA credit will be available until June 6, 2026.Facilitating Progress in Early Detection & Intervention in Lung Cancer: Proactive Strategies to Improve Lung Cancer Screening for High-Risk Individuals in VA Healthcare Settings In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and National Association of Veterans' Research and Education Foundations. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an independent educational grant from Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/KDS865. CME/MOC/AAPA credit will be available until June 6, 2026.Facilitating Progress in Early Detection & Intervention in Lung Cancer: Proactive Strategies to Improve Lung Cancer Screening for High-Risk Individuals in VA Healthcare Settings In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and National Association of Veterans' Research and Education Foundations. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an independent educational grant from Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/KDS865. CME/MOC/AAPA credit will be available until June 6, 2026.Facilitating Progress in Early Detection & Intervention in Lung Cancer: Proactive Strategies to Improve Lung Cancer Screening for High-Risk Individuals in VA Healthcare Settings In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and National Association of Veterans' Research and Education Foundations. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an independent educational grant from Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/KDS865. CME/MOC/AAPA credit will be available until June 6, 2026.Facilitating Progress in Early Detection & Intervention in Lung Cancer: Proactive Strategies to Improve Lung Cancer Screening for High-Risk Individuals in VA Healthcare Settings In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and National Association of Veterans' Research and Education Foundations. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an independent educational grant from Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/KDS865. CME/MOC/AAPA credit will be available until June 6, 2026.Facilitating Progress in Early Detection & Intervention in Lung Cancer: Proactive Strategies to Improve Lung Cancer Screening for High-Risk Individuals in VA Healthcare Settings In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and National Association of Veterans' Research and Education Foundations. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an independent educational grant from Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

“A lot of other disease sites, they have some targeted therapies, they have some immunotherapies [IO]. In lung cancer, we have it all. We have chemo. We have IO. We have targeted therapies. We have bispecific T-cell engagers. We have orals, IVs. I think it's just so important now that, particularly for lung cancer, you have to be well versed on all of these,” ONS member Beth Sandy, MSN, CRNP, thoracic medical oncology nurse practitioner at the Abramson Cancer Center at the University of Pennsylvania in Philadelphia, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about lung cancer treatment. Music Credit: “Fireflies and Stardust” by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by May 16, 2026. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to lung cancer treatments. Episode Notes  Complete this evaluation for free NCPD.  ONS Podcast™ episode: Episode 359: Lung Cancer Screening, Early Detection, and Disparities ONS Voice articles: Non-Small Cell Lung Cancer Prevention, Screening, Diagnosis, Treatment, Side Effects, and Survivorship Oncology Drug Reference Sheet: Amivantamab-Vmjw Oncology Drug Reference Sheet: Cisplatin Oncology Drug Reference Sheet: Lazertinib Oncology Drug Reference Sheet: Nivolumab and Hyaluronidase-Nvhy Oncology Drug Reference Sheet: Fam-Trastuzumab Deruxtecan-Nxki Optimize Your Testing Strategy and Improve Patient Outcomes With NeoGenomics' Neo Comprehensive™–Solid Tumor Assay Clinical Journal of Oncology Nursing article: Oncogenic-Directed Therapy for Advanced Non-Small Cell Lung Cancer: Implications for the Advanced Practice Nurse ONS Biomarker Database ONS video: What is the role of the KRAS biomarker in NSCLC? Biomarker Testing in Non-Small Cell Lung Cancer Discussion Tool ONS Huddle Cards: Checkpoint inhibitors External beam radiation Monoclonal antibodies Proton therapy To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode “Unfortunately, because lung cancer is pretty aggressive, we'll see lung cancer mostly in stage IV. So about 50%–55% of all cases are not caught until they are already metastatic, or stage IV. And then about another 25%–30% of cases are caught in stage III, which means they're locally advanced and often not resectable, but we do still treat that with curative intent with concurrent chemoradiation. And then 10%–20% of cases are found in the early stage, and that's stage I and II, where we can do surgical approaches.” TS 2:53 “The majority of radiation that you're going to see is for patients with stage III disease that's inoperable. At my institution, a lot of stage III is inoperable. Now, neoadjuvant immunotherapy has changed that a little bit. But if you have several big, bulky, mediastinal lymph nodes that makes you stage III, surgery is probably not going to be a great option. So we give curative-intent chemoradiation to these patients.” TS 10:51 “Oligoprogression would mean they have metastases but only to one site. And sometimes we will be aggressive with that. Particularly, there's good data, if the only site of progression is in the brain, we can do stereotactic radiation to the brain and then treat the chest with concurrent chemoradiation as a more definitive approach. But outside of that, the majority of stage IV lung cancer is going to be treated with systemic therapy.” TS 15:00 “It's important for nurses to know that there's a lot of different options now for treatment. Probably one of the most important things is making sure patients are aware of what their biomarker status is, what their PD-L1 expression level is, and make sure those tests have been done. … It's good that the patients understand that there's a myriad of options. And a lot of that depends on what we know about their cancer, and then that guides our treatment.” TS 31:05

In this episode of Thinking Thoracic, hear from Alexandra Potter, researcher, and Dr. Chi-Fu Jeffrey Yang, both from Massachusetts General Hospital, about a new study that reveals current lung cancer screening guidelines miss nearly half of patients who develop the disease. Alternative approaches could greatly expand access—especially for women, minorities, and former smokers. 

In this episode, Dr. Mark Meeker, VP and Chief Medical Officer at OSF St. Mary and Holy Family Medical Centers, shares how OSF is using FirstLook Lung, a groundbreaking blood test, to enhance early lung cancer detection—dramatically improving survival outcomes and streamlining care pathways.

In this episode, Dr. Mark Meeker, VP and Chief Medical Officer at OSF St. Mary and Holy Family Medical Centers, shares how OSF is using FirstLook Lung, a groundbreaking blood test, to enhance early lung cancer detection—dramatically improving survival outcomes and streamlining care pathways.

It has been more than a decade since lung cancer screening guidelines via low-dose CT, based on the USPSTF's B recommendations, have been put into place. To discuss the guidelines' ambitions and obstacles, we are joined by the University of Illinois Health System's Mary Pasquinelli, DNP, who specializes in lung cancer, lung cancer screening and pulmonary nodule management. While a lifesaving procedure for at-risk individuals, the uptake of screening on a population-level—though increasing—has been slower than expected. Want more Lungcast? Visit us at HCPLive.com/podcasts/lungcast or www.lung.org/professional-education/lungcast

Episode 359: Lung Cancer Screening, Early Detection, and Disparities “I was actually speaking to a primary care audience back a few weeks ago, and we were talking about lung cancer screening. And they said, ‘Our patients, they don't want to do it.' And I said, ‘Do you remind them that lung cancer is curable?' Because everybody thinks it is a death sentence. But when you're talking about screening a patient, I think it's really important to say, ‘Listen, if we find this early, stage I or stage II, our chances of curing this and it never coming back again is upwards of 60% to 70%,'” ONS member Beth Sandy, MSN, CRNP, thoracic medical oncology nurse practitioner at the Abramson Cancer Center at the University of Pennsylvania in Philadelphia, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about lung cancer screening. Music Credit: “Fireflies and Stardust” by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by April 18, 2027. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to lung cancer screening. Episode Notes  Complete this evaluation for free NCPD.  ONS Podcast™ episodes: Episode 313: Cancer Symptom Management Basics: Other Pulmonary Complications Episode 295: Cancer Symptom Management Basics: Pulmonary Embolism, Pneumonitis, and Pleural Effusion Episode 247: Tobacco Treatment for Patients With Cancer ONS Voice articles: Lung Cancer Screening and Early Detection Drastically Improves Survival Rates Pack-Year History Is a Biased and Inadequate Criterion for Lung Cancer Screening Eligibility, Researchers Say CMS Expands Eligibility Criteria for Lung Cancer Screening With Low-Dose Computed Tomography Non-Small Cell Lung Cancer Prevention, Screening, Diagnosis, Treatment, Side Effects, and Survivorship Clinical Journal of Oncology Nursing articles: Nurse-Led Tobacco Cessation for Veterans Using Motivational Interviewing in a Lung Cancer Screening Program Identifying Primary Care Patients at High Risk for Lung Cancer: A Quality Improvement Study Oncology Nursing Forum article: Patient–Provider Discussion About Lung Cancer Screening Is Related to Smoking Quit Attempts in Smokers ONS Tobacco, E-Cigarettes, and Vaping Learning Library American Cancer Society Lung Cancer Screening Guidelines American Lung Association lung cancer resources To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast Club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode “Unfortunately, the current state of lung cancer screening is pretty low. Our rate of uptake in eligible patients is somewhere between 6% and 20%. And that falls much further below what we see for screening, such as breast cancer screening, prostate cancer screening, and colorectal cancer screening. So certainly, we can do better.” TS 1:32 “If you quit more than 15 or 20 years, your risk of developing lung cancer at that point is significantly lower. And so that's why once patients have quit more than 15 years, they're actually not eligible for screening anymore—because their risk of developing lung cancer is dramatically reduced. And that takes into account when you are a primary care provider, pulmonary, whatever field you work in, and you are running a screening clinic each year that you screen the patient, you have to remind yourself when they quit smoking, because once they reach that 15 years, then they're no longer eligible for screening.” TS 5:17 “One of the strategies that they've used to get the word out is, I watch a lot of baseball. I love the Philadelphia Phillies, watch Phillies games. And so at least once a year, maybe even twice a year, they will take an inning of the baseball broadcast on TV and on the radio separately, and they will bring on either an oncologist or pulmonologist from one of the local cancer centers in our area, and the whole inning—between batters of course—they will talk about lung cancer screening and why it's beneficial.” TS 13:16 “Medicare always has its idiosyncrasies. So Medicare—I went over the rules with you, so the age, the smoking. They follow all of it, except they have a slight difference in age. They cover it for age 50 to 77, as opposed to 80.” TS 16:52 “I think just the other thing that people don't think about is that to go get a medical test done, no matter what test it is, typically people have to take time off of work. And it can be really hard to do that when you are relying on your job, maybe you don't have vacation time, maybe you have children at home that you need to get home to. When people are weighing the risk/benefit and thinking, ‘Well, I'd love to get screened for lung cancer, but I just can't find time to fit it into my schedule, and my job won't let me take off.' These are all things that we don't always think about if you have the luxury of just taking the day off.” TS 20:01

Less than 20% of patients eligible for lung cancer screening get screened in the US. A recent study examined whether adults eligible for lung cancer screening engage in screening for other types of cancer. Coauthor Chi-Fu Jeffrey Yang, MD, of Harvard Medical School joins JAMA Deputy Editor Tracy Lieu, MD, to discuss. Related Content: Preventive Health Care Use Among Adults Eligible for Lung Cancer Screening in the US

This week on The Beat, CTSNet Editor-in-Chief Joel Dunning examines how to prevent adverse publicity by patients on social media. Chapters 00:00 Intro 02:01 Patient-Social Media Interaction 11:56 Lung Cancer Screening Recommendations 15:29 Perc vs Surg Revasc, SWEDEHEART Registry 18:06 Down Syndrome Patient Outcomes 19:20 Nighttime Cardiovascular Staffing Impact 23:42 Samurai Cannulation 28:30 Off-Pump AAD Via Upper Ministernotomy 30:35 Robotic Thoracic Truncal Vagotomy 31:59 Upcoming Events 33:02 Closing He explores the benefits and drawbacks of patient groups on social media, explains how social media impacted the Shanghai Pulmonary Hospital, and provides examples of online patient groups. He also discusses whether surgeons should encourage patients to post on social media, what roles surgeons should have in online patient groups, and discusses his own experience with online patient groups.   Joel also reviews recent JANS articles on lung cancer screening and USPSTF recommendations, percutaneous vs. surgical revascularization of non-ST-segment elevation myocardial infarction with multivessel disease, outcomes in adult congenital heart disease patients with Down syndrome undergoing a cardiac surgical procedure, and the impact of nighttime cardiovascular intensive care unit staffing on failure to rescue and revenue.   In addition, Joel explores Samurai (the Direct True Lumen Technique) cannulation in acute type I aortic dissection, off-pump aortic arch debranching via upper ministernotomy, and robotic thoracic truncal vagotomy. Before closing, he highlights upcoming events in CT surgery.   JANS Items Mentioned  1.) Lung Cancer Screening and USPSTF Recommendations   2.) Percutaneous vs. Surgical Revascularization of Non-ST-Segment Elevation Myocardial Infarction With Multivessel Disease: The SWEDEHEART Registry  3.) Outcomes in Adult Congenital Heart Disease Patients With Down Syndrome Undergoing a Cardiac Surgical Procedure  4.) Impact of Nighttime Cardiovascular Intensive Care Unit Staffing on Failure to Rescue and Revenue  CTSNET Content Mentioned  1.) Samurai (the Direct True Lumen Technique) Cannulation in Acute Type I Aortic Dissection  2.) Off-Pump Aortic Arch Debranching Via Upper Ministernotomy  3.) Robotic Thoracic Truncal Vagotomy  Other Items Mentioned  1.) Career Center   2.) CTSNet Events Calendar  Disclaimer The information and views presented on CTSNet.org represent the views of the authors and contributors of the material and not of CTSNet. Please review our full disclaimer page here.

In this episode of Inside INdiana Business with Gerry Dick, we explore the transformation of the Indiana State Fairgrounds into a year-round event destination. With 400 events annually—from conventions and sports tournaments to food competitions—the fairgrounds now generate a $330 million economic impact. We take an inside look at the investments fueling this growth and what it means for central Indiana's economy. Plus, Indiana's first-ever mobile lung cancer screening unit hits the road. We'll meet the team behind this 40-foot CT scanner on wheels, designed to bring life-saving early detection directly to Hoosiers in rural areas. Also in this episode: The State Fairgrounds' big sports play: How a state-of-the-art indoor track is attracting national competitions and boosting local revenue. A look inside Jim Irsay's multimillion-dollar collection: From Bob Dylan's electric guitar to Muhammad Ali's iconic fight robe, we go behind the scenes with the Colts owner's world-class artifacts. Indiana's role in March Madness: With 43 postseason college basketball games in Indianapolis this month, we break down the city's economic impact and what's ahead for 2026, when Indy hosts all major NCAA men's championships. The latest in Indiana's auto industry: How tariffs could impact thousands of Honda workers in Greensburg, and what the future holds for the state's manufacturing sector.

In this episode of Inside INdiana Business with Gerry Dick, we explore the transformation of the Indiana State Fairgrounds into a year-round event destination. With 400 events annually—from conventions and sports tournaments to food competitions—the fairgrounds now generate a $330 million economic impact. We take an inside look at the investments fueling this growth and what it means for central Indiana's economy. Plus, Indiana's first-ever mobile lung cancer screening unit hits the road. We'll meet the team behind this 40-foot CT scanner on wheels, designed to bring life-saving early detection directly to Hoosiers in rural areas. Also in this episode: The State Fairgrounds' big sports play: How a state-of-the-art indoor track is attracting national competitions and boosting local revenue. A look inside Jim Irsay's multimillion-dollar collection: From Bob Dylan's electric guitar to Muhammad Ali's iconic fight robe, we go behind the scenes with the Colts owner's world-class artifacts. Indiana's role in March Madness: With 43 postseason college basketball games in Indianapolis this month, we break down the city's economic impact and what's ahead for 2026, when Indy hosts all major NCAA men's championships. The latest in Indiana's auto industry: How tariffs could impact thousands of Honda workers in Greensburg, and what the future holds for the state's manufacturing sector.

This week Bobbi Conner talks with MUSC's Dr. Nichole Tanner about annual lung cancer screening for individuals at an increased risk of lung cancer.

Lung cancer is the leading cause of cancer-related deaths, but early detection can change that. In this episode, Dr. Bill Evans sits down with thoracic surgeon Dr. Christian Finley to discuss the urgent need for lung cancer screening, the latest advancements in early detection, and how a simple, low-dose CT scan can dramatically improve survival rates. DisclaimerThe Cancer Assist Show is hosted by Dr. Bill Evans, MD, FRCP, Past President of the Juravinski Hospital and Cancer Centre at HHS. Brought to you by the Cancer Assistance Program—an organization lending support to cancer patients and families of those affected by cancer. --- The Cancer Assist Show and its content represent the opinions of Dr. Bill Evans and guests to the podcast. Any views and opinions expressed by Dr. Bill Evans and guests are their own and do not represent those of their places of work. The content of The Cancer Assist Show is provided for informational, educational and entertainment purposes only, and is not intended as professional medical, legal or any other advice, or as a substitute or replacement for any such advice. The Cancer Assist Program, Dr. Bill Evans and guests make no representations or warranties with respect to the accuracy or validity of any information or content offered or provided by The Cancer Assist Show. For any medical needs or concerns, please consult a qualified medical professional. No part of The Cancer Assist Show or its content is intended to establish a doctor-patient or any other professional relationship. This podcast is owned and produced by the Cancer Assistance Program.

Lung cancer screening is vital to detecting cancer early, when it is easier to treat and more likely to be cured. Interventional Pulmonologist, Preeti Patel, MD, explains how the screening works and who should be getting this potentially life-saving test.Support the showSarah Bush Lincoln is a 150-bed, not-for-profit, regional health system located in East Central Illinois. Follow us on: Faceboook InstagramLinkedIn

Lung Cancer Screening Guidelines and Care with guest Dr. Lynn Tanoue, November 24, 2024 Yale Cancer Center visit: www.yalecancercenter.org email: canceranswers@yale.edu call: 203-785-4095

A traveling, mobile lung screening program has the potential to diagnose cancer earlier, leading to a higher cure rate and lower death rate. In this episode of Thinking Thoracic, STS's new podcast series, host Dr. Jeffrey Yang talks with Dr. Robert Headrick about CHI Memorial's “Breathe Easy” mobile lung screening program and how meeting people where they are with quality healthcare services like this one is saving lives. Learn how to build a mobile lung screening program at a hospital and gain tips on assembling a multidisciplinary team, identifying eligible patient populations, securing funding and the necessary equipment, and more.

A traveling, mobile lung screening program has the potential to diagnose cancer earlier, leading to a higher cure rate and lower death rate. In this episode of Thinking Thoracic, STS's new podcast series, host Dr. Jeffrey Yang talks with Dr. Robert Headrick about CHI Memorial's “Breathe Easy” mobile lung screening program and how meeting people where they are with quality healthcare services like this one is saving lives. Learn how to build a mobile lung screening program at a hospital and gain tips on assembling a multidisciplinary team, identifying eligible patient populations, securing funding and the necessary equipment, and more.

In this episode, we speak with Dr. Natalie Lui, Assistant Professor of Cardiothoracic Surgery at Stanford University, about lung cancer screening and the importance of early detection. Since lung cancer is often diagnosed in advanced stages, yearly low-dose computed tomography (LDCT) screening is crucial, especially for heavy smokers. We discuss risk factors, screening criteria from the U.S. Preventive Services Task Force, National Comprehensive Cancer Network, and the American Cancer Society, and why screening isn't universal despite its importance. Additionally, we explore current research, recent updates to guidelines, barriers to screening in underserved communities, and the potential of emerging technologies, such as AI, to enhance lung cancer screening in the future. Read Transcript CME Information: https://stanford.cloud-cme.com/medcastepisode92 Claim CE: https://stanford.cloud-cme.com/Form.aspx?FormID=3122

With fewer smokers today, the number of Americans getting lung cancer has dropped. However, the decline has been slower in women. Not only are they diagnosed, on average, at a younger age than men, but multiple studies have found that women between the ages of 30 and 49 are developing the disease at higher rates compared to men in the same age group. November is lung cancer awareness month: In this episode, lung cancer experts Brett Bade, MD, and Nagashree Seetharamu, MD, MBBS, join host Sandra Lindsay, RN, to discuss the alarming trend in women and to raise awareness about lung cancer screening in general; currently, less than 10% of people who should be checked for lung cancer actually get screened. Learn the criteria for screening, what the scan is like and how to lower the risk of developing the disease. Read more about this episode on the Northwell Newsroom. Chapters:  02:34 - Lung cancer risk factors 03:32 - Health effects of smoking 04:11 - Second hand smoking 05:14 - Are there early signs of lung cancer?  05:54 - What is lung cancer screening? 07:37 - Low-dose CT lung cancer screening 08:27 - Who is eligible for screening? 08:50 - What if you don't qualify for screening but have a risk factor? 10:31 - What barriers to screening exist? 11:28 - Low screening numbers 12:45 - Lung cancer in young women 14:15 - Sex differences in lung cancer 14:34 - Differences in lung cancer in women 15:41 - EGFR mutation and lung cancer 16:19 - EGFR, Asian woman and lung cancer 17:13 - Breaking down racial disparities 18:49 - Barriers to lung cancer screening About the experts: Dr. Bade is a pulmonologist and the director of the Lung Cancer Screening Program at Lenox Hill Hospital (Patients and providers can call 844-544-5864). Dr. Seetharamu is the head of thoracic and head and neck oncology for Northwell Health. She maintains an active clinical practice at the R.J. Zuckerberg Cancer Center, specializing in cancers of the head and neck and thoracic malignancies (lung cancer, mesothelioma, thymic tumors). She is also Associate Professor of Medicine at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell. Read Dr. Bade's op-ed on lung cancer screening guidelines.

Dr. Leila Rezai explores the updated 10 Pillars of Lung Cancer Screening in light of COPD and Lung Cancer Awareness Month. Dr. Rezai discusses key developments since 2015, including changes in eligibility, the need for patient education, and innovative strategies to enhance screening access. RadioGraphics Update: The 10 Pillars of Lung Cancer Screening—Rationale and Logistics of a Lung CancerScreening Program Adams et al. RadioGraphics 2023; 44(3):e230057.  

Dr. May Lin Tao explains who should be screened for lung cancer, why it's important, and what's involved.

 Lung cancer screenings save lives by detecting cancer early, but only 1.7 percent of eligible Oklahomans get screened. TSET and OU Health are teaming to bring screening to more people by launching a Mobile Lung Cancer Screening bus this fall. Episode 48 provides insights on lung cancer screening from OU Health thoracic surgeon Dr. J. Matthew Reinersman and a person who shares their personal experience with screening, and information on the bus from Terry Rousey, TSET associate director of statewide initiatives.

Prof. Marcus Kennedy, Consultant respiratory physician, Cork University Hospital & President Irish Thoracic society

In this episode we speak with Bellinda King-Kallimanis, PhD, an expert in oncology research and patient advocacy. Bellinda shares her diverse experience in the field, from academia to the FDA and now her role at LUNGevity Foundation. The conversation covers various aspects of lung cancer, including screening procedures, risk factors, and common misconceptions. Bellinda emphasizes the importance of early detection and addresses the stigma associated with lung cancer. We also delve into the Patient-Centered Outcomes Research Institute (PCORI) and a study comparing the impact of using different types of material to communicate screening information to patients. The episode also includes a rapid-fire Q&A section, where Bellinda provides concise explanations of key terms and concepts related to lung cancer. This episode was supported by the Patient Centered Outcomes Research Institute (PCORI) and features this PCORI study by Robert J. Volk, PhD. Key Highlights: 1. Lung cancer screening compliance is strikingly low at 5-6%, despite high risk for those with tobacco history, and additional requirements may further complicate the process. 2. Stigma surrounding lung cancer, primarily due to its association with smoking, can deter people from seeking screening or discussing their health history, despite the fact that people with no tobacco history or people who have not smoked can also develop the disease. 3. Patient involvement in research, through initiatives like citizen science programs, and improved communication of complex information are crucial for advancing lung cancer care and understanding. About our guest: Dr. Bellinda King-Kallimanis is Senior Director of Patient-Focused Research at LUNGevity Foundation. In her work at LUNGevity she aims to ensure that patient and caregiver voices are incorporated in decision making across a wide variety of stakeholders and has built a Citizen Scientist program to aid this. Prior to joining LUNGevity, she worked at the US Food and Drug Administration Oncology Center of Excellence on the Patient Focused Drug Development team. There, she worked on the development and launch of Project Patient Voice, a resource for patients and caregivers along with their healthcare providers to look at patient-reported symptom data collected from cancer clinical trials. Bellinda also has experience in industry and academia and has published over 70 peer-reviewed papers. She received her Bachelor of Social Science and Master of Science in applied statistics from Swinburne University of Technology in Melbourne, Australia, and her PhD in psychometrics from the Academic Medical Center in Amsterdam, Netherlands. Key Moment: At 38:39 “I've taken it on to try to improve my communication as a researcher, because we spend so many years reading complex materials that you just start talking that way. It does not resonate with my family. They'll be like, what are you talking about? Who do you think you are? So if we really want to be able to talk to people and connect the work we do, then we have to be able to talk about it in much simpler terms. I really do think it's so important for us all to work on our abilities to make sure that we are speaking to each other versus, I've been in plenty of conversations where people are not speaking, they're just speaking around each other because there's a gap in the understanding and healthcare is already like very complex and cancer is really scary. So,just being aware of not talking in acronyms all the time.” Visit the ⁠Manta Cares Website⁠ Disclaimer: All content and information provided in connection with Manta Cares is solely intended for informational and educational purposes only.  This content and information is not intended to be a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

Lung cancer is Australia's deadliest cancer. When patients develop symptoms like coughing it is generally no longer curable by surgery or other treatments.The National Lung Cancer Screening Program will begin next year and will involve routine scanning in the hope of catching the disease in its earliest stages. More information, including who's eligible for the Program, is available hereThis podcast is brought to you by Macquarie University Hospital, a part of MQ Health.Professor of Respiratory Medicine at Macquarie University Hospital, Alvin Ing told the MJA the screening program could push the cure rate for lung cancer to as high as 90%,

Lung cancer remains Australia's deadliest cancer. A new screening program, to be introduced in 2025, is expected to save hundreds of lives each year.But for those who have the disease now, how does a multi-disciplinary team work to improve lung cancer care? How are best outcomes created? And how far has Artificial Intelligence and robotic technology evolved in treating this disease?To answer these questions and more, leading Cardiothoracic Surgeon Professor Michael Wilson speaks with The MJA's news and online editor, Sally Block.This podcast is sponsored by Macquarie University Hospital.

Resources provided by podcast participants:National Lung Cancer Round Table-https://nlcrt.org/Lung Plan- https://nlcrt.org/lungplan-overview/Standing Facility Lung Program-https://cancer.wvumedicine.org/about-us/programs/lung-cancer-screening-programMobile Lung Program- https://cancer.wvumedicine.org/about-us/programs/mobile-cancer-screening-program/lucasLiving Beyond Cancer Podcast Series(Patient, Survivors, and Caregivers)-https://cancer.wvumedicine.org/about-us/podcasts/

Howie and Harlan catch up on healthcare headlines, including the politics of treating gun violence as a public health crisis, the growing evidence for the dangers of artificial sweeteners, and the latest on the bird flu outbreak. Links: Aspen Ideas: Health 2024 Harlan Krumholz: “The Next Era of JACC” "First Issue of JACC Debuts Under Harlan M. Krumholz" "U.S. clinical trials begin for twice-yearly HIV prevention injection" UNAIDS: 2023 Fact Sheet Rush University System: Dr. Omar B. Lateef "Rush Signs on as First Partner for Local Laundry Service" “Health Equity as a System Strategy: The Rush University Medical Center Framework” "Surgeon General Declares Gun Violence a Public Health Crisis" Surgeon General's Advisory on Firearm Violence "Surgeon General: Why I'm Calling for a Warning Label on Social Media Platforms" “Patient Navigation for Lung Cancer Screening at a Health Care for the Homeless Program A Randomized Clinical Trial” Vinay Prasad: “CT screening for lung cancer for homeless people: the new JAMA IM paper” Supreme Court: Murthy v. Missouri Opinion "US supreme court allows government to request removal of misinformation on social media" Harlan Krumholz: “Why One Cardiologist Has Drunk His Last Diet Soda" “Xylitol is prothrombotic and associated with cardiovascular risk” "Is Xylitol Dangerous?" CDC: A(H5N1) Bird Flu Response Update June 21, 2024 "Michigan stands out for its aggressive bird flu response. Will other states follow its lead?" "Finland to offer bird flu vaccinations to at-risk residents in a world first" Learn more about the MBA for Executives program at Yale SOM. Email Howie and Harlan comments or questions.

Interview with Priti Bandi, PhD, author of Lung Cancer Screening in the US, 2022, and Ilana B. Richman, MD, MHS, author of Progress in Lung Cancer Screening Adoption. Hosted by Eve Rittenberg, MD. Related Content: Lung Cancer Screening in the US, 2022 Progress in Lung Cancer Screening Adoption

Interview with Priti Bandi, PhD, author of Lung Cancer Screening in the US, 2022, and Ilana B. Richman, MD, MHS, author of Progress in Lung Cancer Screening Adoption. Hosted by Eve Rittenberg, MD. Related Content: Lung Cancer Screening in the US, 2022 Progress in Lung Cancer Screening Adoption

In this podcast, Bahram Mohajer, MD, MPH, explores the study by Park et al. on the use of AI models to automate the evaluation for coronary artery calcification on low-dose lung cancer screening CT scans, as well as the correlation of AI findings with major adverse cardiovascular events. ARTICLE TITLE - Coronary Artery Calcification on Low-Dose Lung Cancer Screening CT in South Korea: Visual and Artificial Intelligence-Based Assessment and Association with Cardiovascular Events

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/PJP865. CME/MOC/AAPA/IPCE credit will be available until April 16, 2025.Screening and Early Intervention as the Keys to Success in Lung Cancer: A Practical Approach to Implementing Lung Cancer Screening for High-Risk Individuals In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and LUNGevity Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Merck & Co., Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/PJP865. CME/MOC/AAPA/IPCE credit will be available until April 16, 2025.Screening and Early Intervention as the Keys to Success in Lung Cancer: A Practical Approach to Implementing Lung Cancer Screening for High-Risk Individuals In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and LUNGevity Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Merck & Co., Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/PJP865. CME/MOC/AAPA/IPCE credit will be available until April 16, 2025.Screening and Early Intervention as the Keys to Success in Lung Cancer: A Practical Approach to Implementing Lung Cancer Screening for High-Risk Individuals In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and LUNGevity Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Merck & Co., Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/PJP865. CME/MOC/AAPA/IPCE credit will be available until April 16, 2025.Screening and Early Intervention as the Keys to Success in Lung Cancer: A Practical Approach to Implementing Lung Cancer Screening for High-Risk Individuals In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and LUNGevity Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Merck & Co., Inc.Disclosure information is available at the beginning of the video presentation.

Dr. Centor discusses the real-world complications of lung cancer screening with Drs. Katharine A. Rendle and Anil Vachani.

Live and Learn with Katie, Learn Something New! In this impactful video, Katie from MOMnation and Carla from the American Cancer Society come together to raise awareness about the critical importance of early detection and lung cancer screening, especially for individuals who have a history of smoking. Carla courageously shares her personal journey as a lung cancer survivor, shedding light on the challenges she faced and the hope she found through early detection and treatment. As Katie and Carla discuss the sobering statistics surrounding lung cancer, they emphasize the fact that early detection can significantly improve outcomes and save lives. They highlight the American Cancer Society's commitment to providing resources and support for individuals at risk of or affected by lung cancer, including access to screening programs, informational materials, and community networks. - Learn More About the Hope Lodge - https://bit.ly/3uvZwKp - How to Stay Away from Tobacco - https://bit.ly/3HXrlye Carla's firsthand account serves as a powerful reminder of the importance of being proactive about one's health, regardless of past smoking habits. She shares how her decision to undergo a lung cancer screening ultimately led to the detection of the disease at an early stage, enabling her to receive timely treatment and improve her chances of survival. Throughout the video, Katie and Carla underscore the message that no smoker is immune to the risk of lung cancer, and early detection can make all the difference in the fight against this devastating disease. By encouraging viewers to prioritize their health and take advantage of available screening resources, they aim to empower individuals to take control of their well-being and potentially save lives. Don't miss this heartfelt discussion about the importance of early detection and the invaluable support provided by organizations like the American Cancer Society. Join Katie and Carla as they advocate for greater awareness, access to screening, and support for those affected by lung cancer, offering hope and encouragement to viewers everywhere. - Cancer Screening Recommendations - https://bit.ly/49SX6EP - Climb to Conquer Cancer of Phoenix - https://bit.ly/3SDtc07 - Join the MOMnation team for the Climb! - https://fb.me/e/5jfsbzB2y - Online Help - www.cancer.org - Chat live or call 800.227.2345 - The American Cancer Society 24/7 cancer helpline provides information and answers for people dealing with cancer. They can connect you with trained cancer information specialists who will answer questions about a cancer diagnosis and provide guidance and a compassionate ear. While the American Cancer Society doesn't provide individual financial support, their specialists can help refer individuals to patient-related programs or resources in your local area. Follow and connect with the American Cancer Society: Facebook - https://www.facebook.com/americancancersocietyarizona/ Instagram - https://www.instagram.com/acsarizona/ LinkedIn - https://www.linkedin.com/company/acsarizona YouTube - https://www.youtube.com/amercancersociety X - http://www.twitter.com/americancancer Brought to you by Team EvoAZ at eXp Realty and MOMnation Connect and Follow us at https://direct.me/momnationaz or http://MOMnationUSA.com

Dr. Lauren Kim discusses results from the 20-year follow-up of the International Early Lung Cancer Action Program with Dr. Claudia Henschke, Dr. Rowena Yip, and Dr. David Yankelevitz. A 20-year Follow-up of the International Early Lung Cancer Action Program (I-ELCAP). Henschke and Yip et al. Radiology 2023; 309(2):e231988.

The new James mobile lung cancer screening unit is on the road, traveling around the state of Ohio. This is a big step forward because “lung cancer still accounts for more cancer deaths than breast cancer, colon cancer and prostate cancer combined,” said Michael Wert, MD, a James pulmonologist and director of the James lung cancer screening program. “I still see too many patients who haven't seen a doctor in a while, ignore symptoms and come in so sick that we'll do a CT scan and find they have really advanced lung cancer.” In this episode, Wert talks about the goals for the screening unit and why it is so vital. Smoking is the primary cause of lung cancer. “The new screening guidelines for lung cancer are that people aged 50 to 80 with a 20-pack-year history should be screened,” Wert said. “This means someone who has smoked a pack a day for 20 years, or two packs a day for 10 years.” Even people who have quit smoking years ago, but had a 20-pack-year history, need to be screened. “Too many people think what I don't know can't hurt me, but this isn't true, but this fear may prevent people from getting screened,” Wert said. Reaching out to underserved communities is vital in reducing cancer deaths. “Right, now, the major screening centers in Ohio are in the big cities,” Wert said. “And the highest risk patients for lung cancer often lives hours away from the nearest screening facility … We're one of only five or six mobile lung cancer screening units in the country and we're at the cutting edge of this. So, if you live in a remote area, don't be discouraged, our mobile lung cancer screening unit will be coming to you one day and don't let your fears or anxieties of finding an abnormality scare you away. My hope is we'll take our mobile screening unit to a town and hundreds of cars will be lined up waiting for us.”